Acquiring evidence for precision prostate cancer care

<span class="paragraphSection">In the current issue of Annals of Oncology, Romero-Laorden et al. [<a href="#mdx105-B1" class="reflinks">1</a>] report the case of a patient with metastatic castration-resistant prostate cancer (mCRPC) who achieved a significant tumour response to the PARP inhibitor veliparib administered as a single agent. Molecular studies on this patient's primary and metastatic tumour tissue samples revealed a homozygous deletion of <span style="font-style:italic;">BRCA2</span> as the putative mechanism determining PARP inhibitor sensitivity, although the authors describe genomic heterogeneity for this event within the primary tumour.</span>

http://ift.tt/2pchqPv